<DOC>
	<DOCNO>NCT00997945</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics single multiple dos 10mg ZD4054 ( Zibotentan ) male , elderly Chinese patient advance solid malignancy .</brief_summary>
	<brief_title>10mg ZD4054 ( Zibotentan ) PK Study Male , Elderly Chinese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Provision inform consent Histological and/or cytological confirm advanced solid malignancy WHO performance status &lt; 2 History significant gastrointestinal impairment , judge investigator , could significantly affect absorption ZD4054 ( Zibotentan ) , include ability swallow tablet whole . ALT AST³2.5 ´ULRR . If liver metastasis present ALT AST 5times ULRR , Serum bilirubin &gt; 1.5 x ULRR , Serum creatinine &gt; 1.5 x ULRR creatinine clearance &lt; 50mL/min calculated CockroftGault Recent ( &lt; 14 day ) major surgery prior entry study , surgical incision fully heal , Radical radiotherapy within previous 4 week , unresolved acute subacute toxicity prior radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Phase I , advance solid malignancy , advance solid tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>ZD4054 ( Zibotentan )</keyword>
	<keyword>china</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>